Research Progress of Metronomic Chemotherapy in the Treatment of Elderly Cancer Patients
DOI:
https://doi.org/10.54097/rc7brb68Keywords:
Metronomic Chemotherapy, Elderly Cancer Patients, Cancer Burden, Low-Dose Chemotherapy, Treatment Tolerance, Angiogenesis Inhibition, Quality of LifeAbstract
In China, elderly individuals (≥60 years) face a growing cancer burden, accounting for 55.8% of new cases and 68.2% of deaths. Metronomic chemotherapy offers a promising approach by using continuous low-dose treatment to inhibit tumor growth with fewer side effects. breaking through the cycle-dependent limitations of traditional chemotherapy, this review discusses its applications and benefits for elderly cancer patients, aiming to support clinical practice, at the same time, significantly improves patient compliance and the quality of life of elderly patients.
Downloads
References
[1] Cao, G.W., Epidemiological Characteristics, Current Prevention Status, and Future Strategies of Cancer in China. Academic Journal of Naval Medical University, 2025. 46(03): p. 279-290.
[2] Camerini, A., et al., Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial). BMC Cancer, 2015. 15: p. 359.
[3] Cazzaniga, M.E., et al., Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study. Breast Cancer Research and Treatment, 2016. 160(3): p. 501-509.
[4] Cerrito, M.G., et al., Metronomic combination of vinorelbine and 5-fluorouracil inhibits triple-negative breast cancer cells: results from the proof-of-concept VICTOR-0 study. Oncotarget, 2018. 9(44): p. 27448-27459.
[5] Crivellari, D., et al., Adjuvant pegylated liposomal doxorubicin for older women with endocrine-nonresponsive breast cancer unsuitable for standard chemotherapy: the CASA randomized trial. Breast, 2013. 22(2): p. 130-137.
[6] Davies, E.A. & M.S. O’Mahony, Adverse drug reactions in special populations—the elderly. British Journal of Clinical Pharmacology, 2015. 80(4): p. 796-807.
[7] Deng, L.C., et al., Clinical efficacy of capecitabine metronomic chemotherapy combined with celecoxib in advanced colorectal cancer. Modern Medicine, 2011. 39(04): p. 434-436.
[8] D’Ascanio, M., et al., Metronomic chemotherapy with vinorelbine in frail elderly patients with advanced non-small cell lung cancer: clinical benefit and low toxicity. Biomedical Research International, 2018. 2018: p. 6278403.
[9] Ferrara, N., H.P. Gerber & J. LeCouter, The biology of VEGF and its receptors. Nature Medicine, 2003. 9(6): p. 669-676.
[10] Frenel, J.S., et al., Durvalumab and tremelimumab combined with metronomic oral vinorelbine for recurrent advanced cervical cancer: an open-label phase I/II study. Journal for Immunotherapy of Cancer, 2025. 13(1).
[11] Fu, X., et al., Role of autophagy in vinorelbine-induced apoptosis of lung cancer cell line A549. Chinese Journal of Lung Cancer, 2008(03): p. 345-348.
[12] Ge, Y., et al., Immunological effects and clinical outcomes of metronomic cyclophosphamide in metastatic breast cancer patients. Cancer Immunology, Immunotherapy, 2012. 61(3): p. 353-362.
[13] Ghiringhelli, F., et al., Metronomic cyclophosphamide selectively depletes CD4+CD25+ regulatory T cells and restores T/NK effector functions in end-stage cancer patients. Cancer Immunology, Immunotherapy, 2007. 56(5): p. 641-648.
[14] Gustafson, C.E., et al., Influence of immune aging on vaccine responses. Journal of Allergy and Clinical Immunology, 2020. 145(5): p. 1309-1321.
[15] Han, B., et al., Cancer incidence and mortality in China, 2022. Journal of the National Cancer Center, 2024. 4(1): p. 47-53.
[16] Hanahan, D., G. Bergers & E. Bergsland, Less is more, regularly: metronomic dosing of cytotoxic drugs targets tumor angiogenesis in mice. Journal of Clinical Investigation, 2000. 105(8): p. 1045-1047.
[17] He, M.Y., Efficacy and safety of pyrotinib combined with capecitabine metronomic chemotherapy in HER2-positive advanced breast cancer. 2024.
[18] He, S.Y., et al., Age distribution and trend of breast cancer burden in global and Chinese women. China Oncology, 2023. 32(01): p. 1-7.
[19] He, Y., et al., Clinical efficacy of capecitabine metronomic chemotherapy in maintenance treatment of elderly metastatic breast cancer. Practical Geriatrics, 2018. 32(04): p. 327-329, 334.
[20] Jia, J.K. & L.S. Liu, Interpretation of Chinese Expert Consensus on Drug Treatment of Geriatric Metabolic Syndrome (2022). Chinese Journal of Clinical Healthcare, 2024. 27(01): p. 43-46.
[21] Ju, W., et al., Cancer statistics in Chinese older adults, 2022: current burden, time trends, and comparisons with the US, Japan, and South Korea. Science China (Life Sciences), 2023. 66(05): p. 1079-1091.
[22] Kaczanowski, S., Apoptosis: its origin, history, maintenance and the medical implications for cancer and aging. Physical Biology, 2016. 13(3): p. 031001.
[23] Kareva, I., D.J. Waxman & G.L. Klement, Metronomic chemotherapy: an alternative to maximum tolerated dose therapy activating anti-tumor immunity and minimizing resistance. Cancer Letters, 2015. 358(2): p. 100-106.
[24] Kelley, R.K., et al., A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. British Journal of Cancer, 2013. 109(7): p. 1725-1734.
[25] Kerbel, R.S. & B.A. Kamen, The anti-angiogenic basis of metronomic chemotherapy. Nature Reviews Cancer, 2004. 4(6): p. 423-436.
[26] Klement, G., et al., Therapeutic index differences of combination metronomic chemotherapy and anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clinical Cancer Research, 2002. 8(1): p. 221-232.
[27] Kubota, H., et al., Feasibility of metronomic chemotherapy with tegafur-uracil, cisplatin, and dexamethasone for docetaxel-refractory prostate cancer. Journal of Rural Medicine, 2017. 12(2): p. 112-119.
[28] Kyei, K.A., H.B. Addo & J. Daniels, Radiation safety: knowledge, attitudes, practices, and socioeconomic impact in resource-limited radiotherapy settings. Ecancermedicalscience, 2025. 19: p. 1855.
[29] Li, B.J., J.H. Ding & J.M. Hong, Capecitabine metronomic chemotherapy in 22 cases of metastatic colorectal cancer. Southeast National Defense Medical Journal, 2010. 12(03): p. 247-248.
[30] Li, T.Y., et al., Trends and factor decomposition of lung cancer burden in global and China, 1990–2021. China Oncology, p. 1-13.
[31] Li, X., et al., Research progress of metronomic chemotherapy in elderly advanced breast cancer. Beijing Medical Journal, 2024. 46(08): p. 679-683.
[32] Levy, J.M.M., C.G. Towers & A. Thorburn, Targeting autophagy in cancer. Nature Reviews Cancer, 2017. 17(9): p. 528-542.
[33] Lu, J.F., D. Pokharel & M. Bebawy, A novel mechanism governing the transcriptional regulation of ABC transporters in MDR cancer cells. Drug Delivery and Translational Research, 2017. 7(2): p. 276-285.
[34] Lu, X.D., T.R. Zhang & T. Zhao, Efficacy of capecitabine metronomic chemotherapy in maintenance treatment of advanced triple-negative breast cancer. Journal of Modern Oncology, 2022. 30(13): p. 2365-2368.
[35] Luan, X., Mechanistic study on tumor vessel "normalization" induced by targeted nanoparticles (F56-PTX-NP) via "metronomic chemotherapy". 2016.
[36] Lyon, A.R., et al., Baseline cardiovascular risk assessment for cancer patients receiving cardiotoxic therapies: a position statement and risk tools from the Cardio-Oncology Study Group. European Journal of Heart Failure, 2020. 22(11): p. 1945-1960.
[37] Ma, X.Y., et al., Incidence, mortality, and risk factors of colorectal cancer in China, 1990 vs. 2021. Journal of Practical Oncology, 2025. 40(02): p. 114-119.
[38] Ning, S.F. & C.H. Lin, Efficacy of capecitabine metronomic chemotherapy in maintenance treatment of elderly metastatic breast cancer. Northern Pharmacy, 2019. 16(12): p. 82-83.
[39] Norrby, K., Metronomic chemotherapy and anti-angiogenesis: can upgraded preclinical assays improve clinical trials for tumor growth control? Apmis, 2014. 122(7): p. 565-579.
[40] Pandey, A., et al., Outcome of operable oral cavity cancer and impact of maintenance metronomic chemotherapy: A retrospective study from rural India. South Asian Journal of Cancer, 2016. 5(2): p. 52-55.
[41] Pasini, F., et al., Oral metronomic vinorelbine (OMV) in elderly or pretreated patients with advanced non-small cell lung cancer: real-world outcomes and pharmacokinetics. Investigational New Drugs, 2018. 36(5): p. 927-932.
[42] Pasquier, E., M. Kavallaris & N. André, Metronomic chemotherapy: new rationale for new directions. Nature Reviews Clinical Oncology, 2010. 7(8): p. 455-465.
[43] Pepe, F.F., et al., Immunomodulatory effects of metronomic vinorelbine (mVRL) with/without capecitabine (mCAPE) in HR+/HER2- metastatic breast cancer: final results of phase 2 Victor-5. BMC Cancer, 2022. 22(1): p. 956.
[44] Perroud, H.A., et al., Quality of life in metastatic breast cancer patients treated with metronomic chemotherapy. Future Oncology, 2016. 12(10): p. 1233-1242.
[45] Pfeffer, C.M. & A.T.K. Singh, Apoptosis: a target for anticancer therapy. International Journal of Molecular Sciences, 2018. 19(2).
[46] Pu, Y.H. & X.Y. Wang, Research progress on metronomic chemotherapy for metastatic breast cancer. Frontiers of Medicine, 2024. 14(14): p. 30-33.
[47] Qian, Y.D., et al., Clinical safety of chemotherapy in elderly cancer patients with hypertension. Asian Pacific Journal of Cancer Prevention, 2014. 15(22): p. 9875-9877.
[48] Robey, R.W., et al., Revisiting the role of ABC transporters in multidrug-resistant cancer. Nature Reviews Cancer, 2018. 18(7): p. 452-464.
[49] Ruan, Y.Q., Efficacy and safety of sintilimab combined with vinorelbine metronomic chemotherapy in advanced NSCLC. 2024.
[50] Shi, F. & Y. Yu, Mechanism of metronomic chemotherapy inhibiting tumor growth via angiogenesis and immune system modulation. Journal of Practical Oncology, 2017. 31(04): p. 316-320.
[51] Song, X.N., et al., Effects of PD-1-targeted nano-delivery system on gastric cancer cell activity and T cell immune response factors. China Medical Devices, 2025. 40(01): p. 143-148.
[52] Tang, F.R., et al., Research progress in pharmacokinetics of metronomic chemotherapy. Chinese Journal of Hospital Pharmacy, 2019. 39(04): p. 412-418.
[53] Tian, R., et al., Effects of Huachansu Capsule combined with metronomic chemotherapy on tumor microenvironment and CXCR7/CXCR4 in non-small cell lung cancer. Chinese Journal of Traditional Chinese Medicine and Pharmacy, p. 1-6.
[54] Ueno, T., et al., A multicenter phase II trial of neoadjuvant letrozole plus low-dose cyclophosphamide in postmenopausal ER+ breast cancer (JBCRG-07): efficacy and circulating endothelial cells. Cancer Medicine, 2018. 7(6): p. 2442-2451.
[55] Wang, C., et al., Suppression of colorectal cancer xenografts and lung metastasis via nanoparticle-mediated delivery to tumor neovasculature. Biomaterials, 2014. 35(4): p. 1215-1226.
[56] Wang, X.Q., Z.X. Zhan & L.F. Liao, Effect of capecitabine combined with thalidomide metronomic chemotherapy on quality of life in advanced colorectal cancer. Chinese Journal of Rational Drug Use, 2018. 15(11): p. 42-44.
[57] Wu, L.M. & C.T. Wu, Clinical efficacy of metronomic chemotherapy in elderly advanced gastric cancer. China Foreign Medical Treatment, 2020. 39(34): p. 38-40.
[58] Xu, Y., et al., Therapeutic effect and side effects of bevacizumab combined with irinotecan in pediatric intracranial tumors: a meta-analysis and systematic review. Journal of Clinical Pharmacy and Therapeutics, 2020. 45(6): p. 1363-1371.
[59] Yan, S., et al., Efficacy and safety comparison of metronomic vs. conventional chemotherapy in elderly advanced colorectal cancer. China Foreign Medical Treatment, 2017. 36(33): p. 117-119.
[60] Yang, D.Z., et al., Danggui Buxue Decoction combined with capecitabine metronomic chemotherapy in elderly advanced colorectal cancer. Jilin Journal of Chinese Medicine, 2019. 39(08): p. 1032-1036.
[61] Yeh, T.J., et al., Efficacy and outcomes of metronomic tegafur-uracil chemotherapy in locally advanced head and neck squamous cell carcinoma: a real-world cohort experience. Biology (Basel), 2021. 10(2).
[62] You, H., et al., Low-dose antineoplastic agents promote tumor angiogenesis via bone marrow-derived cells in tumor tissues. Frontiers in Pharmacology, 2024. 15: p. 1414832.
[63] Yue, J. & P. Yuan, Metronomic Chemotherapy and Survival Extension in Advanced Cancer Patients. Chinese Journal of Clinical Physicians, 2018. 46(04): p. 387-389.
[64] Zhang, X.C., Efficacy of Capecitabine Combined with Zibu Decoction in Advanced Colorectal Cancer with Qi-Blood Deficiency After First-Line Chemotherapy. Journal of Chronic Diseases, 2020. 21(06): p. 859-860.
[65] Zheng, R., et al., Cancer Incidence and Mortality in China, 2016. Journal of the National Cancer Center, 2022. 2(1): p. 1-9.
[66] Zhu, Y., et al., Clinical Research Progress of Metronomic Chemotherapy in Elderly Tumor Patients. China Pharmaceuticals, 2024. 33(11): p. 117-122.
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

